Wadensten H, Ekebacke A, Hammarberg B, Holmgren E, Kalderén C, Tally M, Moks T, Uhlén M, Josephson S, Hartmanis M
KabiGen AB, S-112 87 Stockholm, Sweden.
Biotechnol Appl Biochem. 1991 Jun;13(3):412-21.
Human insulin-like growth factor II (IGF-II) was produced in an Escherichia coli ompT strain as a 22.5-kDa fusion protein. IGF-II was fused to the carboxy-terminal of a synthetic 15-kDa IgG-binding protein, originating from staphylococcal protein A, via a unique methionine linker. During fermentation, the fusion protein was exported to the growth medium at levels exceeding 900 mg/liter and subsequently affinity purified on IgG Sepharose followed by ion exchange on S Sepharose. After chemical cleavage with CNBr, yielding an authentic IGF-II molecule, the recombinant IGF-II was purified to homogeneity by a two step procedure involving ion-exchange and reverse-phase HPLC. A substantial fraction of the secreted protein was found to be biologically active, eliminating the need for complex refolding procedures. The yield of highly purified and biologically active IGF-II was 5-7 mg/liter of fermenter broth. The IGF-II produced by this method displayed biochemical, immunological, receptor binding, and biological activity properties equal to those of native IGF-II isolated from human serum.
人胰岛素样生长因子II(IGF-II)在大肠杆菌ompT菌株中作为一种22.5 kDa的融合蛋白产生。IGF-II通过一个独特的甲硫氨酸接头与源自葡萄球菌蛋白A的15 kDa合成IgG结合蛋白的羧基末端融合。在发酵过程中,融合蛋白以超过900 mg/升的水平分泌到生长培养基中,随后在IgG琼脂糖上进行亲和纯化,接着在S琼脂糖上进行离子交换。用溴化氰进行化学裂解后,得到一个天然的IGF-II分子,重组IGF-II通过涉及离子交换和反相高效液相色谱的两步法纯化至同质。发现很大一部分分泌蛋白具有生物活性,无需复杂的复性程序。高纯度且具有生物活性的IGF-II的产量为每升发酵液5 - 7 mg。通过这种方法产生的IGF-II表现出与从人血清中分离的天然IGF-II相同的生化、免疫、受体结合和生物活性特性。